Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KIFC1 | Q9BW19 | 8/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7417219 | 0.85 | LMNA (0.54) | MAPTTP53POLBKIFC1MAPK1 | |
| SCHEMBL11355645 | 0.78 | POLB (0.55) | MAPTPOLBMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL27612413 | 0.76 | L3MBTL1 (0.62) | MAPTL3MBTL1TP53POLBMAPK1 | |
| SCHEMBL6564261 | 0.75 | L3MBTL1 (0.60) | MAPTL3MBTL1TP53POLBMAPK1 | |
| SCHEMBL13273862 | 0.75 | MAPT (0.63) | MAPTL3MBTL1TP53POLBMAPK1 | |
| SCHEMBL29176877 | 0.75 | L3MBTL1 (0.56) | MAPTL3MBTL1TP53POLBKIFC1 | |
| SCHEMBL8311929 | 0.74 | L3MBTL1 (0.72) | MAPTL3MBTL1TP53POLBMAPK1 | |
| SCHEMBL8168563 | 0.74 | MAPT (0.53) | MAPTTP53POLBLMNAGAA | |
| SCHEMBL29860111 | 0.74 | MAPT (0.53) | MAPTTP53POLBLMNAGAA | |
| SCHEMBL30955278 | 0.74 | CNR1 (0.49) | MAPTTP53POLBSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166694-A1 | Glycinamides | MERCK PATENT GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166694-A1 | Glycinamides | F11, SERPINC1, F13A1 | MAPT 4813/4885L3MBTL1 1904/4885TP53 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.